Nanoparticles could have giant impact on drug development

05/7/2013 | Reuters

Bind Therapeutics has agreed to three deals potentially worth a total of $1 billion to help drugmakers develop nanomedicine. Drugs incorporating nanoparticles of polymers, gold and graphene are in various stages of development, including 117 oncology drugs, according to Thomson Reuters Pharma. Nanoparticles may allow targeted treatment of tumors with fewer side effects than conventional therapies and may also be useful in drugs for inflammatory disorders, pain, and heart and brain diseases, as well as diagnostics.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY